Innovative Continuous Glucose Monitoring: twiist™ Meets Eversense® 365
Published: 20 Feb 2026
Author: Precedence Research
The landscape of diabetes care in the U.S. has taken a significant technological leap forward as Sequel Med Tech, LLC, and Senseonics Holdings, Inc. They announced the nationwide rollout of the twiist Automated Insulin Delivery (AID) System integrated with the Eversense 365 Continuous Glucose Monitoring (CGM) platform. It is the first time a one-year implantable CGM has been combined with an automated insulin delivery system.
This has been introduced to provide patients with diabetes with a more implantable and continuous glucose monitoring and insulin delivery system. The integration is a significant step toward simplifying the cumbersome, complicated old system for managing diabetes, which requires frequent sensor replacements and manual corrections.
The key to this new development is the incorporation of the smart insulin delivery system of Twiist with the unprecedented life of Eversense 365 CGM. This is already the only system of implantable glucose monitoring on the market that can run for up to 12 months without a replacement. The twiist system enables users to achieve the best possible glucose levels with the smallest amount of manual effort.
Using the Tidepool software platform to automatically adjust insulin delivery to the body in response to real-time glucose readings. This consolidation indicates an increasing trend of complete automated and customized management of diabetes systems that are aimed at enhancing the quality of life and clinical outcomes. Furthermore, the future of long-duration implantable sensors and automated delivery systems is projected to be a pillar of diabetes management in the world as innovation persists.
Executives’ Statements
Joanna Mitri, M.D., M.S., Chief Medical Officer at Sequel Med Tech, emphasized the importance of expanding patient choice and improving quality of life, stating, “As the first automated insulin delivery system to integrate with a year-long continuous glucose monitor, twiist represents a meaningful step forward. People living with diabetes deserve technology that adapts to their lives, reduces daily burden, and provides reliable, personalized support for long-term care.”
Brian Hansen, Chief Commercial Officer of Senseonics, highlighted the significance of the national launch, saying, “The full U.S. availability of Eversense 365 integrated with twiist marks an important milestone in advancing diabetes management. By combining long-term glucose monitoring with intelligent insulin delivery, we are enabling individuals to spend less time managing devices and more time focusing on their health and daily lives.”